<DOC>
	<DOCNO>NCT00093756</DOCNO>
	<brief_summary>This phase I/II trial ( phase I close accrual 09/29/2009 ) study side effect best dose bortezomib , paclitaxel , carboplatin give radiation therapy see well work treat patient stage IIIA stage IIIB non-small cell lung cancer remove surgery . Bortezomib may stop growth tumor cell block enzymes necessary growth . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop tumor cell divide stop grow die . Bortezomib may increase effectiveness paclitaxel carboplatin make tumor cell sensitive drug . Radiation therapy use high-energy x-rays damage tumor cell . Giving bortezomib , paclitaxel , carboplatin together radiation therapy may kill tumor cell .</brief_summary>
	<brief_title>Bortezomib , Paclitaxel , Carboplatin Radiation Therapy Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose bortezomib , paclitaxel , carboplatin administer fractionated radiotherapy patient unresectable stage IIIA IIIB non-small cell lung cancer . ( Phase I ) ( close accrual 09/29/2009 ) II . Determine 1-year survival patient treat regimen . ( Phase II ) SECONDARY OBJECTIVES : I . Determine tolerability regimen patient . ( Phase II ) II . Determine response rate , progression-free survival , overall survival patient treat regimen . ( Phase II ) III . Correlate p27 expression tumor tissue survival , time progression , response patient treat regimen . ( Phase II ) OUTLINE : This multicenter , phase I ( close accrual 09/29/2009 ) , dose-escalation study bortezomib , paclitaxel , carboplatin follow phase II study . PHASE I : ( close accrual 09/29/2009 ) Patients receive bortezomib IV day 1 , 4 , 8 , 11 . Patients also receive paclitaxel IV 3 hour follow carboplatin IV 30 minute day 2 . Patients undergo radiotherapy daily day 1-5 , 8-12 , 15-19 . Treatment repeat every 3 week 2 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bortezomib , paclitaxel , carboplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . PHASE II : Patients receive bortezomib , paclitaxel , carboplatin phase I MTD . Patients also undergo radiotherapy phase I . Patients follow periodically 5 year time registration .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Locally advanced stage IIIA IIIB disease consider unresectable No stage IV disease Requires radiotherapy Performance status ( PS ) Eastern Cooperative Oncology Group ( ECOG ) 01 At least 12 week Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) aspartate aminotransferase ( AST ) ≤ 3 time ULN Creatinine ≤ 1.5 time ULN No New York Heart Association class III IV heart disease Forced expiratory volume ( FEV ) FEV_1 ≥ 1 L OR 35 % predict Weight loss &lt; 10 % within past 3 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No peripheral neuropathy ≥ grade 2 No severe underlie disease would preclude study participation No uncontrolled infection No unhealed wound within past 2 week No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , adequately treat noninvasive carcinoma ( carcinoma situ ) , localized prostate cancer No concurrent prophylactic filgrastim ( GCSF ) sargramostim ( GMCSF ) No prior systemic chemotherapy NSCLC* No prior radiotherapy chest More 2 week since prior major surgery Contraindications Any follow : Pregnant wome Nursing woman Men woman childbearing potential sexual partner unwilling employ adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , abstinence , etc . ) regimen may harmful develop fetus nursing child NOTE : This study involve investigational agent whose genotoxic , mutagenic teratogenic effect develop fetus newborn unknown . Any following prior therapy : Prior radiation therapy chest Prior systemic chemotherapy NSCLC ( phase II portion ) New York Heart Association classification III IV ( see Appendix II ) . Any severe underlying disease , judgment investigator , inappropriate entry study . uncontrolled infection . Major surgery unhealed wound ≤ 2 week prior registration . Prior history malignancy ≤ 5 year , except adequately treat basal cell squamous cell skin cancer , adequately treat noninvasive carcinoma ( carcinoma situ ) , localized prostate cancer . Peripheral neuropathy ≥grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>